ANXA1 and glioblastoma: Hence, we hypothesized that ANXA1 could increase IL‐8 levels in patients with GBM through aberrant NF‐κB activation, subsequently affecting DC maturation; this consequently impairs the antigen presentation function of DCs and suppresses immunity in patients with GBM.